The association between pre-treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stage IV prostate cancer

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Gupta, Digant ^a   Trukova, Kristen ^a   Popiel, Brenten ^a   Lammersfeld, Carolyn ^a   Vashi, Pankaj G ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; SERUM ALBUMIN; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; AGE; ARTICLE; BONE METASTASIS; CALCIUM BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; SURVIVAL TIME; UNIVARIATE ANALYSIS; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MORTALITY; PATHOLOGY; PROSTATE TUMOR; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SURVIVAL RATE; VITAMIN D;

EID: 84925067896     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119690     Document Type: Article

References (33)

1. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009; 94:26-34. doi: 10.1210/jc. 2008-1454 PMID: 18854395
2. Holick MF. Vitamin D status: Measurement, interpretation, and clinical application. Ann Epidemiol. 2009; 19:73-78. doi: 10.1016/j.annepidem.2007.12.001 PMID: 18329892
3. Vuolo L, Di Somma C, Faggiano A, Colao A. Vitamin D and cancer. Front Endocrinol (Lausanne). 2012; 3:58. doi: 10.3389/fendo.2012.00058 PMID: 22649423
4. Welsh J. Vitamin D and cancer: Integration of cellular biology, molecular mechanisms and animal models. Scand J Clin Lab Invest Suppl. 2012; 243:103-11. doi: 10.3109/00365513.2012.682870 PMID: 22536770
5. Gupta D, Lammersfeld CA, Trukova K, Lis CG. Vitamin D and prostate cancer risk: A review of the epidemiological literature. Prostate Cancer Prostatic Dis. 2009; 12:215-226. doi: 10.1038/pcan.2009.7 PMID: 19350051
6. Schwartz GG. Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy. Ann Epidemiol. 2009; 19:96-102. doi: 10.1016/j.annepidem.2008.03.007 PMID: 18619854
7. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011; 128:1414-1424. doi: 10.1002/ijc.25439 PMID: 20473927
8. Yin L, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol. 2009; 33:435-445. doi: 10.1016/j.canep.2009.10.014 PMID: 19939760
9. Ren C, Qiu MZ, Wang DS, Luo HY, Zhang DS, Wang ZQ, et al. Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer. J Transl Med. 2012; 10:16. doi: 10.1186/1479-5876-10-16 PMID: 22284859
10. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009; 27:3757-3763. doi: 10.1200/JCO.2008.20.0725 PMID: 19451439
11. Vrieling A, Hein R, Abbas S, Schneeweiss A, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: A prospective patient cohort study. Breast Cancer Res. 2011; 13:R74. doi: 10.1186/bcr2920 PMID: 21791049
12. Fedirko V, Riboli E, Tjonneland A, Ferrari P, Olsen A, Bueno-de-Mesquita HB, et al. Prediagnostic 25- hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European ppulations. Cancer Epidemiol Biomarkers Prev. 2012; 21:582-593. doi: 10.1158/ 1055-9965.EPI-11-1065 PMID: 22278364
13. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008; 26:2984-2991. doi: 1200/JCO.2007.15.1027 PMID: 18565885
14. Mezawa H, Sugiura T, Watanabe M, Norizoe C, Takahashi D, Shimojima A, et al. Serum vitamin D levels and survival of patients with colorectal cancer: Post-hoc analysis of a prospective cohort study. BMC Cancer. 2010; 10:347. doi: 10.1186/1471-2407-10-347 PMID: 20594355
15. Moan J, Porojnicu AC, Robsahm TE, Dahlback A, Juzeniene A, Tretli S, et al. Solar radiation, vitamin D and survival rate of colon cancer in Norway. J Photochem Photobiol B. 2005; 78:189-193. PMID: 15708515
16. Fiscella K, Winters P, Tancredi D, Hendren S, Franks P. Racial disparity in death from colorectal cancer: Does vitamin D deficiency contribute? Cancer. 2011; 117:1061-9. doi: 10.1002/cncr.25647 PMID: 20945439
17. Heist RS, Zhou W, Wang Z, Liu G, Neuberg D, Su L, et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol. 2008; 26:5596-5602. doi: 10.1200/JCO.2008.18.0406 PMID: 18936471
18. Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 2007; 25:479-485. PMID: 17290055
19. Robsahm TE, Schwartz GG, Tretli S. The Inverse Relationship between 25-Hydroxyvitamin D and Cancer Survival: Discussion of Causation. Cancers (Basel). 2013; 5:1439-1455. doi: 10.3390/ cancers5041439 PMID: 24202453
20. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009; 100:450-454. doi: 10.1038/sj.bjc.6604865 PMID: 19156140
21. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One. 2011; 6:e18625. doi: 1371/journal.pone.0018625 PMID: 21494639
22. Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 2013; 37:666-670. doi: 10.1016/j.canep.2013.07.005 PMID: 23972671
23. Ersfeld DL, Rao DS, Body JJ, Sackrison JL Jr, Miller AB, Parikh N, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem. 2004; 37:867-874. PMID: 15369717
24. Wootton AM. Improving the measurement of 25-hydroxyvitamin D. Clin Biochem Rev. 2005; 26:33-36. PMID: 16278775
25. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: Application to the Cox regression model. Stat Med. 1992; 11:2093-2109. PMID: 1293671
26. Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2010; 19:927-931. doi: 10.1158/1055-9965.EPI-09-1121 PMID: 20332255
27. Lagunova Z, Porojnicu AC, Grant WB, Bruland O, Moan JE. Obesity and increased risk of cancer: Does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association? Mol Nutr Food Res. 2010; 54:1127-33. doi: 10.1002/mnfr.200900512 PMID: 20512788
28. Vashi PG, Lammersfeld CA, Braun DP, Gupta D. Serum 25-hydroxyvitamin D is inversely associated with body mass index in cancer. Nutr J. 2011; 10:51. doi: 10.1186/1475-2891-10-51 PMID: 21575232
29. Florez H, Martinez R, Chacra W, Strickman-Stein N, Levis S. Outdoor exercise reduces the risk of hypovitaminosis D in the obese. J Steroid Biochem Mol Biol. 2007; 103:679-681. PMID: 17267209
30. Lee P, Greenfield JR, Seibel MJ, Eisman JA, Center JR. Adequacy of vitamin D replacement in severe deficiency is dependent on body mass index. Am J Med. 2009; 122:1056-1060. doi: 10.1016/j. amjmed.2009.06.008 PMID: 19854337
31. Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S. Evidence for alteration of the vitamin Dendocrine system in obese subjects. J Clin Invest. 1985; 76:370-373. PMID: 2991340
32. Schwartz GG, Skinner HG. A prospective study of total and ionized serum calcium and time to fatal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21:1768-1773. doi: 10.1158/1055-9965. EPI-12-0585 PMID: 22914529
33. Tucci M, Mosca A, Lamanna G, Porpiglia F, Terzolo M, Vana F, et al. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis. 2009; 12:94-99. doi: 10.1038/pcan.2008.10 PMID: 18332901